Javascript must be enabled to continue!
Survival and 30-days hospital outcome in hospitalized COVID-19 patients in Upper Egypt: Multi-center study
View through CrossRef
Abstract
Background
Defining the clinical features and associated outcomes of patients diagnosed with corona virus disease (COVID-19) is fundamental to improving our understanding and adequate management of this illness.
The aim of this study
was to identify the demographic data, underlying comorbidities and the mortality related factors of hospitalized patients with COVID-19 in Upper Egypt.
Patients and methods
1064 cases consecutively admitted to isolation hospitals in Upper Egypt. All cases had confirmed COVID-19 infection. The electronic records of the patients were retrospectively revised and the demographic data, clinical manifestations, qSOFA score on admission and 30 days-outcome (ICU admission, death, recovery, referral or still in hospital) were analyzed. Overall cumulative survival in all patients and those > or < 50 years were calculated.
Results
49.2% of the study population were males and 50.8% were females with mean age 49.4±17.8 years-old. On admission, 83.9% were stable with qSOFA score <1, 3% required non-invasive mechanical ventilation, and 2.1% required O2 therapy. Within 30 days, 203 cases (19.1%) required admission to ICU. Death was recorded in 11.7% of cases, 28.7% recovered, 40.5% referred and 19.2% were still under treatment. Determinants of ICU admission and survival in the current study were age > 50, respiratory rate > 24/minute, SaO2 < 89%, qSOFA >1 and need for O2 therapy or NIV. The cumulative survival was 75.3% with the mean survival was 28.1, and 95.2% overall survival was recorded in those aged ≤50 years.
Conclusions
Age older than 50 years old, those with pre-existing DM, initial qSOFA score, requirement for O
2
therapy and NIV from the first day of hospital admission may be associated with unfavorable 30 days- in hospital outcome of COVID-19.
Title: Survival and 30-days hospital outcome in hospitalized COVID-19 patients in Upper Egypt: Multi-center study
Description:
Abstract
Background
Defining the clinical features and associated outcomes of patients diagnosed with corona virus disease (COVID-19) is fundamental to improving our understanding and adequate management of this illness.
The aim of this study
was to identify the demographic data, underlying comorbidities and the mortality related factors of hospitalized patients with COVID-19 in Upper Egypt.
Patients and methods
1064 cases consecutively admitted to isolation hospitals in Upper Egypt.
All cases had confirmed COVID-19 infection.
The electronic records of the patients were retrospectively revised and the demographic data, clinical manifestations, qSOFA score on admission and 30 days-outcome (ICU admission, death, recovery, referral or still in hospital) were analyzed.
Overall cumulative survival in all patients and those > or < 50 years were calculated.
Results
49.
2% of the study population were males and 50.
8% were females with mean age 49.
4±17.
8 years-old.
On admission, 83.
9% were stable with qSOFA score <1, 3% required non-invasive mechanical ventilation, and 2.
1% required O2 therapy.
Within 30 days, 203 cases (19.
1%) required admission to ICU.
Death was recorded in 11.
7% of cases, 28.
7% recovered, 40.
5% referred and 19.
2% were still under treatment.
Determinants of ICU admission and survival in the current study were age > 50, respiratory rate > 24/minute, SaO2 < 89%, qSOFA >1 and need for O2 therapy or NIV.
The cumulative survival was 75.
3% with the mean survival was 28.
1, and 95.
2% overall survival was recorded in those aged ≤50 years.
Conclusions
Age older than 50 years old, those with pre-existing DM, initial qSOFA score, requirement for O
2
therapy and NIV from the first day of hospital admission may be associated with unfavorable 30 days- in hospital outcome of COVID-19.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
T211. COMPARISON OF REHOSPITALIZATION RATE IN INDIVIDUALS WITH SCHIZOPHRENIA CHANGED FROM PALIPERIDONE PALMITATE TO ORAL ANTIPSYCHOTICS
Abstract
Background
Long-acting antipsychotic therapy (LAT) may help effectively manage individuals with schizophrenia by optimi...
Intravenous Vitamin C for Patients Hospitalized With COVID-19
Intravenous Vitamin C for Patients Hospitalized With COVID-19
ImportanceThe efficacy of vitamin C for hospitalized patients with COVID-19 is uncertain.ObjectiveTo determine whether vitamin C improves outcomes for patients with COVID-19.Design...
The burden of persistent symptoms after COVID-19 (long COVID): A Meta-analysis of controlled studies in children and adults
The burden of persistent symptoms after COVID-19 (long COVID): A Meta-analysis of controlled studies in children and adults
Abstract
Background
Previous meta-analyses estimating the prevalence of the post-COVID-19 condition (PCC) were confounded by the lack of negative control groups. This may r...

